Slide 1: Company Presentation
COMPANY PRESENTATION March 2012
Slide 2: Forward Looking Statement
Forward Looking Statement • This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. • This document contains forward-looking statem
Slide 3: Innate Pharma at a glance
Innate Pharma at a glance • Founded in 1999 • Based in Marseilles, France – 80 employees • First First-in-class in class immunotherapy drugs for cancer and inflammatory diseases o Four IPH p programs g brought g to clinic Antibodies modulating o Proprietary preclinical programs innate immunityy agai
Slide 4: Investment Highlights
Investment Highlights Approach validated by recent approvals • Provenge® P ® (Dendreon), (D d ) fifirstt approved d therapeutic th ti vaccine in prostate cancer • Experienced • Yervoy® (Bristol-Myers Squibb), first approved management team immunomodulating mAb in melanoma • Cash horizon to mid- 2015
Slide 5: Antibodies modulating innate immunity
Antibodies modulating innate immunity to fight cancer and inflammation • In cancer, most mAbs approaches target tumor cells • In inflammation, most mAbs approaches target cytokines • Immunomodulating mAbs are a new approach to both indications Cancer Inflammation Rituxan®, Humira®, Herceptin®… Remic
Slide 6: Innate and Adaptive Immunity
Innate and Adaptive Immunity A cooperative system Innate immunity Adaptive immunity CD8 Activating Receptors DIRECT KILLING Stressed CD8 (NCRs, NKG2D, 92 TCR,…) or Inhibitory Receptors transformed (KIR, NKG2A, …) cell Immune CD8 ADCC memory CD16 Killer cells NK T cells NK, CD4 B cells CD4 IMMUN
Slide 7: Checkpoints of adaptive immunity
Checkpoints of adaptive immunity An increasingly crowded area Immune cell APC / Tumor cell AZN (I&I,Preclin) ICOS B7-H2 Amgen (I&I,PhI) Immutep (Onco, PhII) BMS (Onco, Preclin) LAG-3 Immutep/GSK (I&I (I&I, Preclin) TCR MHC BMS (Transplant and I&I, Marketed) Astellas/Maxygen (Transplant, Preclin) CD2
Slide 8: Innate immunity is still an open field
Innate immunity is still an open field Innate Pharma has a leading position Immune cell Tumor cell GSK/Dynavax (I&I,Preclin) GSK/D (I&I P li ) TLR7/9 Idera (I&I,Preclin) Pathogens J&J (I&I,PhI) TLR3 Inflamed necrotic tissue IPH33 ((I&I,, research)) NKp44 ? NKp46 ? NKp30 B7 H6 B7-H6 BMS (Research) (R
Slide 9: Innate's approach to value creation
Innate’s approach to value creation Early clinical Target sourcing Drug candidate Later development development Antibody engineering ma g Trial design e Pharm Target validation with clinical samples Immunopharmacology Immunomonitoring and biological Efficacy models models Clinical Innate Intellectua
Slide 10: Business Strategy
Business Strategy > Advance and broaden portfolio of proprietary i t d drug candidates did t > Build proprietary > Focus on areas of unmet needs antibody • Initial indications: cancer and chronic inflammation technology platform • Implement internal > Partner products in early stage development high
Slide 11: IPH2102
IPH2102 licensed to Bristol Myers Squibb Bristol-Myers Anti-KIR mAb, first-in-class NK cell modulator, developed in cancer Page 11
Slide 12: IPH2102: $465 million deal with Bristol-Myers Squibb
IPH2102 $465 million deal with Bristol Myers Squibb Bristol-Myers Deal watch: Bristol-Myers Squibb invests in cancer antibody that targets the innate immune system • Largest g license agreement g for a French biotech: Bristol-Myers Squibb S has acquired exclusive global rights to Innate Pharma's can
Slide 13: IPH2102: Activating Natural Killer cells to fight cancer
IPH2102 Activating Natural Killer cells to fight cancer • IPH2102 is a fully human mAb that blocks KIR2DL1/2/3 (“KIR”) ( KIR ) receptors to potentiate the patient’s natural killer (NK) cells to attack tumors o NK cells are the body’s first line of defense against cancer o Cancer cells can proliferat
Slide 14: IPH21, an anti-KIR mAb program
IPH21, an anti-KIR mAb program A new mechanism of action • Targets immune regulatory checkpoints: breaking tolerance to tumor • Fi Firstt drug d candidate did t tto ttargett NK (natural ( t l killer) kill ) cells ll and d activate ti t ththem b by blocking inhibitory receptors MHC from tumor cell is
Slide 15: Therapeutic potential of NK cells
IPH21, an anti-KIR mAb program Therapeutic potential of NK cells • NK cell activation shown to bring clear clinical benefit in bone marrow allografts in acute myeloid leukemia patients • KIR-ligand incompatibility • Also seen in other hematological malignancies including multiple myeloma • NK activa
Slide 16: IPH2201
IPH2201 licensed to Novo Nordisk A/S Fist-in-class anti-NKG2A mAb, developed in inflammation and auto-immune diseases Page 16
Slide 17: NN8765/IPH2201 outlicensed to Novo Nordisk
NN8765/IPH2201 Outlicensed to Novo Nordisk A/S • Activating Natural Killer cells to fight inflammation • Currently in Phase I clinical trials in rheumatoid arthritis > Decision to initiate clinical trials (February 2011) triggered milestone payment > Up U tto €25m €25 in i milestone il t payments t
Slide 18: NN8765/IPH2201: A first in class in inflammation
NN8765/IPH2201 A first in class in inflammation • mAb designed to block NKG2A on subpopulations of NK cells, NKT cells and a subset of T cells > Potentiates their activity to regulate over-activated cells CD8 IPH22, anti- CD8 NKG2A Activatory Receptors Inhibitory Receptors CD8 Overactivated immune c
Slide 19: Proprietary portfolio of new monoclonal antibodies
Proprietary portfolio of new monoclonal antibodies Page 19
Slide 20: IPH41: A cytotoxic mAb targeting KIR3DL2
IPH41 A cytotoxic mAb targeting KIR3DL2 • KIR3DL2 is a new, specific and highly expressed marker of Sezary syndrome (SS) and Transformed Mycosis Fungoides (TMF) o Rare but incurable cutaneous T cell lymphomas o G7 incidence (SS and TMF): 5,000 - 7,000 patients Sezary syndrome Transformed MF Mycosis
Slide 21: IPH33: A blocking mAb targeting TLR3
IPH33 A blocking mAb targeting TLR3 • TLR pharmacology is an active area of development in the industry (GSK, Pfizer, Merck, AstraZenaca J&J). AstraZenaca, J&J) Few programs against TLR3 (one from J&J/Centocor) • Blocking TLR3 aims at preventing inflammatory cytokine production, upstream of current
Slide 22: Key corporate and financial facts
Key corporate and financial facts Page 22
Slide 23: Expected milestones 2012/2013
Expected milestones 2012/2013 Drug candidate Next milestone > Launch of the IPH2102 AML Phase II trial sponsored by IPH IPH21 > BMS program roll out IPH22 > E t in Entry i Phase Ph II by b NN IPH41 > Development candidate qualification IPH33 > Lead candidate identification Undisclosed programs > One
Slide 24: Key 2011 accounting figures
Key 2011 accounting figures Year ended December 31 In thousands of euros 2010 2011 Revenue from collaboration and licensing agreements 211 7,454 Government funding for research expenditures 4,109 4,286 Revenue and other income 4,320 11,740 Research and development expenses (14,041) (14,843) General
Slide 25: Share information and shareholders
Share information and shareholders • Listed on Euronext, IPO in November 2006 • 37.7m shares outstanding (as of December 31, 2011) • Average daily volume >150,000 shares (~0.5% of FF) Shareholder Distribution Page 25
Slide 26: Knowledgeable and highly experienced management team
Knowledgeable and highly experienced management team Hervé Brailly Marcel Rozencweig PhD CEO Co PhD, Co-founder founder MD, Chief Medical Officer MD 30 years of experience in clinical Immunotech SA, Beckman-Coulter drug development Bristol Myers Squibb François Romagné Jérôme Tiollier PhD,, PhD, Chi
Slide 27: Summary
Summary Wh Where we are Where we are Wh 2012 going • 2 partnerships New • Expanded pipeline • Strong cash position programs • Organic growth or by • Recognized experience New acquisition targets throughout g the value • Greater focus on chain clinical stage New technology compounds • 4 products • 2
Slide 28: Appendix
APPENDIX
Slide 29: Cancer and inflammation markets
Cancer and inflammation markets Page 29
Slide 30: Monoclonal antibodies: A $35bn market expected to double
Monoclonal antibodies A $35bn market expected to double by 2015 • mAbs market worth >$35bn and forecast to increase to $63bn in 2015 > Fastest F t t growing i pharmaceutical h ti l segmentt > Expected CAGR 2009/2015 of ~10% vs ~1.5% for the global pharma market • Over 30 mAbs already on the market m
Slide 31: Cancer and inflammation: Markets driven by innovation
Cancer and inflammation Markets driven by innovation • Cancer is a $56bn market, growing at ~10% and mainly driven by sales of antibodies • Biologic treatments for chronic inflammation and auto-immunity is a $30bn+ market > Anti-TNF biologics for rheumatoid arthritis represent a ~ $19bn market (+15%
Slide 32: Scientific positioning
Scientific positioning First-in-class antibodies targeting activation pathways of innate i immunityit cells ll Page 32
Slide 33: Drugs Targeting The Immune System in Oncology
Drugs Targeting The Immune System in Oncology Continuous Innovation Over 30 Years Boosting global Educating the immune system immune reaction against a specific cancer antigen-specific Forcing recognition Selective activation of cancer cells of immune cell subset antigen-specific ti ifi antigen inde
Slide 34: Mechanisms of action in cancer
Mechanisms of action in cancer Boosting immunity / breaking tolerance to tumors Ipilimumab (Yervoy®), anti-PD1 - on T cells, IPH21 - on NK cells CD8 CD8 DIRECT KILLING Tumor Inhibitory Receptors cell CD8 Rituxan®, Herceptin®… IPH41 Killer cells NK, T cells, CD8 CD4 B cells CD4 IMMUNE REGULATION N
Slide 35: Mechanisms of action in inflammation
Mechanisms of action in inflammation Controlling immunity /breaking deleterious immune response CD8 CD8 IPH22 Inflamed or necrotic tissue Activating Receptors Inhibitory Receptors CD8 IMMUNE DOWN O REGULATION CD4 IPH33 B cells Killer cells NK, T cells, CD8 ACTIVATION CD4 Dendritic Naive B cells C
Slide 36: Nobel Prize for innate immunity
Nobel Prize for innate immunity Recognition of innate immunity immunity’s s therapeutic potential • 2011 Nobel Prize for Medicine awarded to Ralph Steinman (Rockefeller, (Rockefeller US) US), Bruce Beutler (Scripps, (Scripps US) and Jules Hoffmann (Strasbourg, France) g • Recognition of Beutler and
Slide 37: Investor relations
Investor relations Laure-Hélène Mercier Director, Investor relations @ p investors@innate-pharma.com Tel: +33 (0)4 30 30 30 87 Fax: +33 (0)4 30 30 30 30 Page 37